Helsinn Gets MHRA Approval for AKYNZEO® Oral Suspension

Lugano, Switzerland, October 29th, 2026, Helsinn Healthcare SA, a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the oral suspension formulation of AKYNZEO® (netupitant/palonosetron). This approval comes after the European Commission Marketing Authorization was granted earlier this year.

The new formulation offers a new therapeutic option for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adults. AKYNZEO® is a 5-HT3 and NK1 receptor antagonist fixed-dose combination approved for these indications. The oral suspension formulation is designed to provide additional flexibility and benefits to a broader range of cancer patients, including those who may have difficulty swallowing.

Helsinn, a third-generation family-owned company, has been operating with integrity, passion, and quality for half a century. Headquartered in Lugano, Switzerland, the company has a commercial presence in 90 countries and a focus on supportive care, oncology, and dermato-oncology. Founded in 1976, Helsinn continues to foster innovation for its patients and embraces sustainable growth as a core element of its strategic vision.

The approval of the oral suspension formulation of AKYNZEO® marks a significant step in expanding therapeutic options for cancer patients, particularly those who may have difficulty swallowing. This new formulation is expected to provide additional flexibility and benefits to a broader range of patients, contributing to the overall quality of care and management of chemotherapy-related side effects.

The approval follows the European Commission Marketing Authorization granted earlier this year, reflecting Helsinn's continued commitment to expanding therapeutic options within its supportive care portfolio and supporting patients throughout their cancer treatment journey. The oral suspension offers a new therapeutic option alongside the currently approved formulations and may provide additional flexibility and benefits to a broader range of cancer patients, including those who may have difficulty swallowing.